REGiMMUNE Corporation is a clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapies aimed at treating rare diseases and cancer. The company leverages decades of scientific research on regulatory T cells (Tregs), which are critical for controlling immune responses. By harnessing these cells, REGiMMUNE aims to induce immune tolerance and achieve potent anti-tumor responses. The company's approach involves using a synthetic small molecule formulated with liposome technology to control the expansion of Tregs, thereby facilitating transplantation tolerance and alleviating autoimmune disease manifestations.

REGiMMUNE operates primarily in the biopharmaceutical market, serving patients with rare diseases and cancer. The business model is centered around developing and commercializing its proprietary immunotherapy treatments. Revenue is generated through a combination of product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.

Keywords: immunotherapy, regulatory T cells, rare diseases, cancer, immune tolerance, transplantation, autoimmune, biopharmaceutical, liposome technology, synthetic molecules.